Elisigen
Latest round
- Series C
Last raised
- Jan 2026
Total raised
- $70M
Investors
- 25
About Elisigen
Based in Seoul, South Korea, and founded in 2018, Elisigen Inc. operates as a biotechnology company that develops gene therapy to treat diseases through in vivo and ex vivo gene transfer methods. In January 2026, Elisigen Inc. Elisigen Inc. provides gene therapy products such as AAV vector-based gene therapy. The company also developed gene therapies for eye diseases such as age-related macular degeneration, chronic neuropathic pain, and cranial nerve diseases such as Alzheimer's disease. In addition, the firm focuses on developing NG101 for wet age-related macular degeneration and NG201 for neuropathic pain.
Who invested in Elisigen
25 investors across 5 rounds
See all investors in Elisigen
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Elisigen
Who invested in Elisigen?
Elisigen has 25 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Elisigen raised?
Elisigen has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did Elisigen last raise money?
Elisigen's most recent round on record is a Series C, in Jan 2026.
What does Elisigen do?
Based in Seoul, South Korea, and founded in 2018, Elisigen Inc.
Where is Elisigen headquartered?
Elisigen is headquartered in Seoul, South Korea.
Which VCs invest in companies like Elisigen?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Elisigen's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Elisigen? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.